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dvances in the Assessment
f No-Reflow After Successful
rimary Percutaneous
oronary Intervention
or Acute ST-Segment
levation Myocardial Infarction
ow That We Can Diagnose It,
hat Do We Do About It?*
aul A. Grayburn, MD, FACC,
ames W. Choi, MD, FACC
allas, Texas
he current standard of care for acute ST-segment elevation
yocardial infarction (STEMI) is primary percutaneous
oronary intervention (PCI), provided that it is available
nd can be performed soon enough after the onset of
ymptoms. However, successful restoration of antegrade
oronary flow with PCI of the “culprit” lesion does not
lways result in myocardial salvage because of the known
isparity between epicardial coronary flow and microvascu-
ar perfusion in the acute myocardial infarction (MI) setting.
See pages 552 and 560
loner et al. (1) first described the no-reflow phenomenon
n dogs with experimental MI. Ito et al. (2) demonstrated
he presence of no-reflow in humans by using intracoronary
yocardial contrast echocardiography (MCE) to show ab-
ence of microvascular perfusion despite successful PCI with
hrombolysis In Myocardial Infarction (TIMI) flow grade
in roughly 25% of patients. No-reflow is associated with
icrovascular plugging by neutrophils and/or microemboli,
erivascular edema, platelet activation, and inflammation
nd may be aggravated by reperfusion injury. Ischemic
reconditioning is known to protect against the no-reflow
henomenon. In clinical studies, no-reflow is associated
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.e
From the Division of Cardiology, Department of Internal Medicine, Baylor
niversity Medical Center, Dallas, Texas.ith worse outcomes, including left ventricular (LV) dys-
unction and death (3,4). Accordingly, the American Col-
ege of Cardiology/American Heart Association guidelines
or management of STEMI have stressed the importance of
valuating the no-reflow phenomenon: “A high priority
xists for the development of simple, accurate, readily
vailable noninvasive techniques to assess the success of
harmacological reperfusion early, i.e., 60 to 90 minutes
fter administration of therapy” (5). In this issue of the
ournal, 2 papers (6,7) have attempted to measure the extent
f microvascular damage associated with the no-reflow
henomenon after successful primary PCI for acute
TEMI.
ndex of Microcirculatory Resistance (IMR)
earon et al. (6) report the results of IMR in 29 patients
ho underwent successful PCI of the infarct artery after
TEMI (primary PCI in 26 and rescue after failed throm-
olysis in 3). Using a pressure/thermistor wire placed
istally in the culprit vessel after PCI, IMR was calculated
s the product of distal coronary pressure and hyperemic
ransit time (derived by thermodilution during intracoro-
ary papaverine or intravenous adenosine). They found that
MR correlated much better with peak creatine kinase
CK) and 3-month echocardiographic wall motion score
han TIMI frame count, myocardial blush grade, coro-
ary flow reserve ratio, or ST-segment resolution. An
MR lower than the median value of 32 U was deemed
easonably good to identify patients whose wall motion
core improved at 3 months. The authors concluded that
MR is an independent predictor of acute microvascular
amage and late (3-month) LV functional recovery. The
tudy has obvious limitations, such as small numbers, use
f peak CK to assess infarct size, potential differences
etween intracoronary papaverine and intravenous aden-
sine, and absence of outcomes. However, the strength of
his approach is that it can be performed in the cathe-
erization laboratory immediately after primary PCI and
hus give the earliest possible estimate of the effect of
rimary PCI on microvascular function. In addition,
MR provides a direct quantitative measure of microvas-
ular function, which is an advantage over TIMI frame
ounts, blush score, or ST-segment resolution.
he AMICI Trial
he authors of the AMICI (Acute Myocardial Infarction
ontrast Imaging) trial (7) studied myocardial perfusion by
sing MCE in 110 consecutive patients who underwent
uccessful primary or rescue PCI within 6 h of STEMI.
hey performed MCE within 1 day of PCI and compared
t with TIMI flow grade, myocardial blush grade, peak CK,
T-segment resolution, and echocardiographic wall motion
core. The end point was LV remodeling, which occurred in
5% of patients and was defined as a 20% increase in LV
nd-diastolic volume at the 6-month follow-up echocardi-
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February 5, 2008:566–8 Editorial Commentgraphy. With the use of multivariate analysis, these re-
earchers found only the endocardial length of the myocar-
ial perfusion defect on MCE and a TIMI score 3 to
redict LV remodeling. In the subset of patients with a
IMI score of 3, only the endocardial length of MCE
erfusion defect predicted LV remodeling. The study could
ave been stronger had more patients been enrolled, had
utcomes been analyzed, and had a more accurate measure-
ent of LV remodeling and infarct size, specifically if cine
agnetic resonance with delayed hyperenhancement, been
sed (8). Moreover, the authors did not take advantage of
he ability of MCE to provide quantitative information
bout myocardial blood volume and microvascular flow
9,10). Nevertheless, the study confirms that MCE, a
irect noninvasive measure of microvascular damage after
TEMI, is superior to subjective and indirect measures
TIMI score, myocardial blush grade, and ST-segment
esolution).
mplications for Treatment
lthough these 2 studies demonstrate the ability to detect
o-reflow early after PCI for STEMI, what do we do with
he information? Unfortunately, the answer is not clear.
lthough several clinical trials have evaluated adjunctive
herapy to address microvascular dysfunction accompanying
TEMI, no therapy has yet been proven to reverse
o-reflow. The EMERALD (European and Australian
ulticenter Evaluative Research on Atrial Fibrillation–
ofetilide) trial (11) showed that distal protection devices
uccessfully remove atheroembolic debris during primary
CI but do not improve survival, microvascular flow,
eperfusion, infarct size, or LV function. The CADILLAC
Controlled Abciximab and Device Investigation to Lower
ate Angioplasty Complications) trial (12) showed primary
tent placement to be superior to primary balloon angio-
lasty, but adjunctive therapy with abciximab did not
mprove outcome. In contrast, the ADMIRAL (Platelet
lycoprotein IIb/IIIa Inhibition With Coronary Stent-
ng for Acute Myocardial Infarction) trial (13) showed
hat abciximab given to patients before primary PCI
mproved TIMI score, LV function, and a composite end
oint of death, nonfatal MI, and target vessel revascular-
zation. However, there is no evidence that abciximab can
alvage established no-reflow. Small studies of intracoro-
ary vasodilators, such as verapamil, nicardipine, and
itroprusside, have shown improved TIMI scores, but
utcomes data are lacking (14–17). The AMISTAD II
rial (18) failed to show improved clinical outcomes in
1,118 patients with STEMI undergoing reperfusion
herapy with adenosine as an adjunctive therapy.
icorandil, a mitochondrial potassium-channel opener,
as been shown to improve microvascular perfuson in
atients with STEMI when given before reperfusion
19,20). Sodium-hydrogen pump inhibitors block intra-
ellular calcium overload; however, large multicenterrials have not shown clinical benefit as adjunctive ther-
py to primary PCI (21,22).
mplications for Future Research
ould the trials of treatment for no-reflow have been
rong? It is possible that failure of therapeutic benefits in
o-reflow patients is related to inclusion of all STEMI
atients, the majority (70% to 75%) of which do not have
o-reflow phenomenon. Thus, the use of IMR or MCE to
dentify no-reflow patients, who are optimal candidates for
djunctive therapies, could affect future trial design. Patients
ith documented no-reflow by these methods could be
andomized to treatment or placebo, using cine magnetic
esonance to assess infarct size and MCE to quantitate
erfusion. In the meantime, we are left to wonder what to
o when we find no-reflow in our patients.
eprint requests and correspondence: Dr. Paul A. Grayburn,
aylor Heart and Vascular Institute, 621 N. Hall Street, Suite
030, Dallas, Texas 75226. E-mail: paulgr@baylorhealth.edu.
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